A detailed history of Mai Capital Management transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mai Capital Management holds 1,674,679 shares of LCTX stock, worth $921,073. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,674,679
Previous 1,638,772 2.19%
Holding current value
$921,073
Previous $1.64 Million 7.02%
% of portfolio
0.02%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$0.8 - $1.12 $28,725 - $40,215
35,907 Added 2.19%
1,674,679 $1.52 Million
Q2 2024

Aug 12, 2024

BUY
$0.89 - $1.47 $131,639 - $217,427
147,910 Added 9.92%
1,638,772 $1.64 Million
Q1 2024

May 08, 2024

BUY
$0.86 - $1.48 $590,834 - $1.02 Million
687,017 Added 85.47%
1,490,862 $2.21 Million
Q4 2023

Feb 09, 2024

SELL
$0.91 - $1.35 $137,267 - $203,638
-150,843 Reduced 15.8%
803,845 $876,000
Q3 2023

Nov 14, 2023

BUY
$1.16 - $1.53 $3,607 - $4,758
3,110 Added 0.33%
954,688 $1.13 Million
Q2 2023

Aug 02, 2023

BUY
$1.26 - $1.53 $663,343 - $805,488
526,463 Added 123.84%
951,578 $1.34 Million
Q1 2023

May 10, 2023

SELL
$1.2 - $1.53 $38,042 - $48,504
-31,702 Reduced 6.94%
425,115 $637,000
Q4 2022

Feb 09, 2023

SELL
$1.02 - $1.5 $66,354 - $97,579
-65,053 Reduced 12.47%
456,817 $534,000
Q3 2022

Nov 15, 2022

BUY
$1.13 - $1.77 $309,772 - $485,218
274,135 Added 110.66%
521,870 $590,000
Q2 2022

Jul 19, 2022

BUY
$1.12 - $1.61 $277,463 - $398,853
247,735 New
247,735 $391,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $93.4M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.